Indications

• Breast Cancer (see Breast Cancer, [[Breast Cancer]]): investigational
• Non-Small Cell Lung Cancer (see Lung Cancer, [[Lung Cancer]]): FDA-approved

---

Pharmacology

• Irreversible Covalent Inhibitor of Receptor Tyrosine Kinases
  • Epidermal Growth Factor Receptor (EGFR)
  • erbB-2 (HER2)

---

Administration

• XXX

Dose Adjustment

• Hepatic
• Renal

---

Adverse Effects

Dermatologic Adverse Effects

• Dry Skin: >10% of cases
• Hand Foot Syndrome (Chemotherapy-Induced Acral Erythema): 1-10% of cases
• Pruritus (see Pruritus, [[Pruritus]]): >10% of cases
• Rash/Dermatitis: >10% of cases

Gastrointestinal Adverse Effects

• Anorexia (see Anorexia, [[Anorexia]]): >10% of cases
• Cheilitis: 1-10% of cases
• Diarrhea (see Diarrhea, [[Diarrhea]]): >10% of cases
• Stomatitis: >10% of cases
• Taste Changes: 1-10% of cases
• Transaminitis: 1-10% of cases

Ophthalmologic Adverse Effects

• Conjunctivitis: 1-10% of cases
• Dry Eyes: 1-10% of cases
• Keratitis: 0.1-1% of cases

Otolaryngologic Adverse Effects

• Epistaxis (see Epistaxis, [[Epistaxis]]): >10% of cases
• Rhinorrhea/Nasal Congestion (see Rhinorrhea, [[Rhinorrhea]]): 1-10% of cases

Pulmonary Adverse Effects

• Interstitial Lung Disease (see Interstitial Lung Disease-Etiology, [[Interstitial Lung Disease-Etiology]]): 0.1-1% of cases

Renal Adverse Effects

• Acute Kidney Injury (AKI) (see Acute Kidney Injury, [[Acute Kidney Injury]]): 1-10% of cases
• Hypokalemia (see Hypokalemia, [[Hypokalemia]]): 1-10% of cases

Other Adverse Effects

• Cystitis: 1-10% of cases
• Dehydration: 1-10% of cases
• Fever (see Fever, [[Fever]]): 1-10% of cases
• Muscle Spasms: 1-10% of cases
• Paronychia: >10% of cases

---

References

• xxx